AAMS Dermatology & Cosmetology · Vol. 1 · Issue 1 · 2024-03-28
Biologics in Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis of Randomized Trials
Nakagawa T, Yamamoto S, Ito H
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan¹; Division of Clinical Research, National Center for Child Health, Tokyo, Japan²
Abstract
Network meta-analysis of 42 randomized controlled trials involving 18,000 patients compares efficacy and safety of dupilumab, tralokinumab, abrocitinib, and upadacitinib for moderate-to-severe atopic dermatitis.
Keywords: Atopic Dermatitis, Biologics, Network Meta-Analysis, Dupilumab, JAK Inhibitors
Full Text
Network meta-analysis of 42 randomized controlled trials involving 18,000 patients compares efficacy and safety of dupilumab, tralokinumab, abrocitinib, and upadacitinib for moderate-to-severe atopic dermatitis.
This article is published open access by AAMS Dermatology & Cosmetology. The complete peer-reviewed text can be read on the journal page.
Author Citation Metrics
Metrics are sourced from public bibliometric records (OpenAlex) and each author's Google Scholar profile.